By a News Reporter-Staff News Editor at Cancer Vaccine Week -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, announced that the Company will ring the NASDAQ Stock Market closing bell on Wednesday, July 16, 2014 in Times Square, New York, NY (see also Biotechnology Companies).
President and CEO Michael H. Tardugno and members of the Celsion and EGEN management teams will participate in the closing bell ringing ceremony from 3:45 pm to 4:00 pm ET. A live webcast will be available at https://new.livestream.com/nasdaq/live.
"Celsion has achieved significant milestones during the first half of 2014, including our recent strategic acquisition of EGEN and the launch of a pivotal, double-blind, placebo-controlled, global Phase III trial (the OPTIMA Study) for our lead development candidate, ThermoDox® in primary liver cancer," said Michael H. Tardugno, Celsion's President and Chief Executive Officer. "Ringing the closing bell at NASDAQ commemorates this progress, which establishes Celsion as a fully integrated oncology development company with multiple product candidates and technology platforms, and a robust development effort with ongoing or planned Phase III, II and I studies."
As previously announced, in June 2014, the Company completed the acquisition of EGEN, a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases. The acquisition includes EGEN's Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas™ for delivery of DNA and mRNA, TheraSilence™ for delivery of RNA, and RAST™ for Cell Enabled Expression and Secretion of RNA. With this acquisition, Celsion is now focused on the leading-edge of cancer treatment, with assets in directed chemotherapies, immunotherapies and DNA- or RNA-based therapies.
Keywords for this news article include: Biotechnology Companies, Biotechnology Company, Cancer, Celsion Corporation, Oncology.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC